FY27-28 Adult Flu Vaccines

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

75D30126R73517

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Atlanta, Georgia, UNITED STATES

SourceSAM
The Centers for Disease Control and Prevention (CDC), operating under the Department of Health and Human Services, has issued a Combined Synopsis/Solicitation for the procurement of adult influenza (flu) vaccines for fiscal years 2027 and 2028. This opportunity, identified by procurement number 75D30126R73517, seeks to establish one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts with qualified suppliers of standard commercial adult vaccines. The primary objective of this procurement is to secure a reliable and cost-effective supply of adult flu vaccines to support immunization programs across the United States. The scope of this procurement is centered on the acquisition of commercially available adult influenza vaccines, with the intent to leverage Section 317 vaccine purchase funds. By utilizing these federal funds, the CDC aims to obtain vaccines at prices more favorable than those typically available in the commercial marketplace. The vaccines procured under these contracts will be distributed to state and local health departments, large city programs, and U.S. territories, all of which are designated as immunization awardees under the National Center for Immunization and Respiratory Diseases (NCIRD). The overarching goal is to enhance immunization coverage among adult populations at greatest risk for under-vaccination and vaccine-preventable diseases. Key requirements for this solicitation include the ability to manufacture and supply standard commercial adult flu vaccines in accordance with all applicable regulatory standards. Contractors must be capable of supporting the needs of a diverse network of public health entities, ensuring timely and efficient delivery to various jurisdictions. In addition to federally funded purchases, awardees may also use state and local funds to procure additional vaccine quantities under any resulting contract, providing flexibility and scalability to meet fluctuating public health demands. The procurement is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with a Product Service Code of 6505, indicating a focus on pharmaceutical and vaccine products. There are no set-aside restrictions for this opportunity, making it open to all qualified vendors regardless of business size or socioeconomic status. The place of performance for this contract is Atlanta, Georgia, which serves as the central hub for CDC operations. The CDC Office of Acquisition Services is the contracting entity responsible for managing this procurement. Interested parties may direct inquiries to the primary contact, Cole Mullis ([email protected]), or the secondary contact, James Sprigler ([email protected]). This solicitation is currently active, with a posting date of September 9, 2026, and a response deadline of September 16, 2026. Additional details, including attachments and submission instructions, can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/ffa74c9b2d134f1bab1723b99440e712/view. Contractors considering this opportunity should have robust capabilities in pharmaceutical manufacturing, distribution logistics, and compliance with federal vaccine procurement standards. The long-term nature of the ID/IQ contract structure and the critical public health mission underscore the importance of reliability, quality, and cost-effectiveness in all deliverables throughout the contract lifecycle.
Documents8